Kohl Justin C, Werner Liliana, Ford Joshua R, Cole Scott C, Vasavada Shail A, Gardiner Gareth L, Noristani Rozina, Mamalis Nick
From the Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
From the Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
J Cataract Refract Surg. 2014 Dec;40(12):2113-9. doi: 10.1016/j.jcrs.2014.10.011. Epub 2014 Nov 24.
To evaluate long-term uveal and capsular biocompatibility of a new accommodating intraocular lens (IOL).
John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
Experimental study.
Bilateral phacoemulsification was performed in 14 rabbits; 1 eye received the accommodating IOL (Fluidvision) and the other received a hydrophobic acrylic control IOL. Slitlamp examinations were performed at postoperative weeks 1 to 4 and months 2, 3, 4, and 6. Six rabbits were humanely killed at 2 months and 8 rabbits at 6 months. After gross examination with the Miyake-Apple view, selected IOLs were removed for implant cytology. All globes were then sectioned and processed for histopathologic examination.
Uveal biocompatibility of study and control IOLs was similar in clinical and pathologic examinations up to 6 months postoperatively. In the study group, anterior capsule opacification appeared absent and posterior capsule opacification (PCO) was significantly less than in the control group. At the gross examination at 6 months, central PCO was 0.8 ± 0.5 (SD) in the study IOLs and 3.7 ± 0.4 in the control IOLs (P < .0001, 2-tailed paired t test). Histopathologic examination confirmed the relative lack of capsule opacification in study eyes compared with controls and the absence of untoward inflammatory reaction or toxicity in all eyes.
The accommodating IOL maintained an expanded capsular bag secondary to the large size of the haptic elements without significant contact with the anterior capsule. This appeared to prevent overall capsular bag opacification and to retain uveal and capsular biocompatibility.
评估一种新型可调节人工晶状体(IOL)的长期葡萄膜和囊膜生物相容性。
美国犹他州盐湖城犹他大学约翰·A·莫兰眼科中心。
实验研究。
对14只兔子进行双侧超声乳化白内障吸除术;一只眼睛植入可调节IOL(Fluidvision),另一只眼睛植入疏水丙烯酸对照IOL。在术后第1至4周以及第2、3、4和6个月进行裂隙灯检查。6只兔子在2个月时被安乐死,8只兔子在6个月时被安乐死。在通过三浦-苹果视图进行大体检查后,取出选定的IOL进行植入细胞学检查。然后将所有眼球切片并进行组织病理学检查。
在术后6个月内,研究组和对照组IOL的葡萄膜生物相容性在临床和病理检查中相似。在研究组中,前囊膜混浊似乎不存在,后囊膜混浊(PCO)明显少于对照组。在6个月时的大体检查中,研究组IOL的中央PCO为0.8±0.5(标准差),对照组IOL为3.7±0.4(P<.0001,双侧配对t检验)。组织病理学检查证实,与对照组相比,研究组眼中囊膜混浊相对较少,且所有眼中均未出现不良炎症反应或毒性。
由于襻元件尺寸较大,可调节IOL使囊袋保持扩张状态,且与前囊膜无明显接触。这似乎可防止整个囊袋混浊,并保持葡萄膜和囊膜的生物相容性。